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S_nmary Syndecans are a family of cell-surface heparan sulphate proteoglycans which are involved in
cell-matrix interactions and growth factor binding. Syndecan-1 binds basic fibroblast growth factor (bFGF)
and several components of the extracellular matrix. Syndecan-l expression is induced dunng keratinocyte
differentiation and reduced during the formation of squamous cell carinomas (SCCs). The purpose of this
study was to examine the association of syndecan-l expression with prognostic factors and clinical outcome in
SCC of the head and neck. Frozen sections of 29 primary SCCs were analysed for syndecan-l expression using
immunohistochemical methods. Intermediate or strong staining for syndecan-l was associated with a smaler
primary tumour size (P = 0.0005) and higher histological grade of differentiation (P = 0.006) than negative or
weakly positive staining. In a univariate analysis, syndecan-l-positive tumours were associated with higher
overall (P = 0.001) and recurrence-free survival (P = 0.003) than those tumours with no or little syndecan-l
expression. The results suggest that syndecan-l could be an important prognostic factor of SCC of the head
and neck. Further studies on the prognostic significance of syndecan-I expression in SCCs are warranted.
Cell adhesion molecules, such as integrins, cadherins and
cell-surface proteoglycans, are involved in the regulation of
cell differentiation, proliferation, morphology and migration
(Gallagher, 1989; Ruoslahti, 1991; Takeichi, 1991; Bernfield
et al., 1992). In the past few years it has become evident that
this group of molecules working in concert is essential for the
maintenance of normal cellular functions. The development
of malignant epithelial tumours is associated with reduced
intercellular adhesion, disturbed differentiation and changes
in the composition of the basement membrane (Weinstein et
al., 1976; Liotta et al., 1986), suggesting that the expression
and function of cell adhesion molecules could also change
during malignant transformation. Indeed, alterations in the
expression of many cell adhesion molecules associated with
the development of carcinomas have been reported (Virtanen
et al., 1990; Inki et al., 1991; Navarro et al., 1991; Schipper
et al., 1991).
Syndecans are a family of cell-surface heparan sulphate
proteoglycans (HSPGs) which have been suggested to par-
ticipate in cell-cell and cell-matrix interactions and the
binding of growth factors (reviewed by Jalkanen et al., 1991,
1993; Bernfield et al., 1992). The primary structure of the
core proteins of four different syndecans, syndecan-l to
syndecan-4, is known to date (reviewed by Bernfield et al.,
1992). All syndecans comprise an extracellular domain con-
taining covalently linked heparan>sulphate chains, a trans-
membrane domain and a relatively short cytoplasmic domain
(Jalkanen et al., 1991; Bernfield et al., 1992). Syndecan-l has
been shown to bind several extracellular matrix molecules via
its heparan sulphate chains, including fibrillar collagens,
fibronectin, thrombospondin and tenascin (Sun et al., 1989;
Elenius et al., 1990; Salmivirta et al., 1991). The localisation
of syndecan-l on the surfaces of stratified epithelial cells
(Hayashi et al., 1987), as well as its expression in mesen-
chymal cell aggregates during organ development (Vainio et
al., 1989), suggests that syndecan-I could also play a role in
cell-cell adhesion. Furthermore, syndecan-l can bind bFGF
(Kiefer et al., 1990; Elenius et al., 1992) and present the
growth factor to the signalling tyrosine kinase receptor
system (Salmivirta et al., 1992). Via binding bFGF,
syndecan-l could be involved in the regulation of the
angiogenic activities of bFGF (Folkman & Shing, 1992) and,
in turn, neovascularisation during the development of malig-
nant neoplasia.
During organ development, syndecan-I production is
induced concomitantly with epithelial-mesenchymal interac-
tions in a developmentally highly regulated fashion (Thesleff
et al., 1988; Sutherland et al., 1991; Vainio & Thesleff, 1992).
In adult tissues, syndecan-I expression is almost entirely
restricted to epithelial tissues, stratified epithelia containing
the most abundant expression (Hayashi et al., 1987; Saunders
et al., 1989). In stratified epithelia, syndecan-l is localised
over the entire surface of keratinocytes, especially in the
suprabasal cell layers, whereas the basal cell layer shows
modest expression (Hayashi et al., 1987; Inki et al., 1991).
Syndecan-I expression is induced during the calcium-induced
differentiation of cultured keratinocytes (Sanderson et al.,
1992; Inki et al., 1994), suggesting that syndecan-l may be
involved in keratinocyte differentiation. However, during
malignant transformation ofkeratinocytes syndecan-l expres-
sion is progressively lost from both premalignant epithelial
lesions and SCCs (Inki et al., 1991, 1992a, 1993). In SCCs,
syndecan-I is localised immunohistochemically in keratinising
cells of the horn pearls in well-differentiated tumours,
whereas poorly differentiated SCCs are devoid of syndecan-l
(In.ki et al., 1992a, 1994). In premalignant lesions of stratified
epithelia, syndecan-I is lost from the basally located, atypical
cell layers (Inki et al., 1991). Loss of syndecan-l from malig-
nantly transformed cells could be one mechanism by which
tumour cells loosen their attachment to each other and to the
extracellular matrix and become non-responsive to the signals
coming from their microenvironment.
The altered expression of syndecan-1 in SCCs and
premalignant lesions of stratified epithelia suggests that
syndecan-I could have prognostic value in the determination
of the clinical outcome of these lesions. This has not been
studied previously. The purpose of this study was to analyse
syndecan-I expression immunohistochemically in frozen sec-
tions of primary SCCs of the head and neck as well as the
relationship between syndecan-I expression and the clinical
outcome in patients with SCC of the head and neck.
Materid and nethos
Patients
Twenty-nine patients histologically diagnosed as having
squamous cell carcinoma of the head and neck between 1988
and 1991, and treated in Turku University Central Hospital,
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were included in the study. The diagnosis and analysis of
syndecan-1 expression were made from biopsy specimens,
which were taken before treatment and immediately snap
frozen in liquid nitrogen. All patients with frozen tissue
available were included in the study. The patient characteris-
tics, treatment given and follow-up status are shown in Table
I. Twenty-two (76%) of the patients were male and seven
(24%) female, and the median age at the time of diagnosis
was 65 years (range 38 to 93 years). The WHO performance
status was determined as described by Miller et al. (1981). All
patients underwent treatment planned to be curative; three
patients were treated with radical surgery, nine with radical
radiotherapy and 17 with the combination of radical surgery
and radiotherapy (Table I). The radiation dose varied from
50 to 72 Gy, with 2 Gy given daily (10 Gy per week). Staging
was done according to the UICC TNM classification (1987).
The patients have been followed up for a median of 25
months after the diagnosis (range 13-41 months) if still
living or until death (17 patients). The overall 2 year survival
rate was 42%.
Histology
All histological material obtained from the tumours was
re-examined and divided into three histologic grades of
differentiation according to the WHO classification (Sham-
ugaratnam & Sobin, 1978) by one pathologist. H&E- and
van Gieson-stained 4;Lm sections were used.
Staining ofsyndecan-J
Syndecan-l was localised in tissue sections using a polyclonal
affinity-purified rabbit antibody (anti-PI17) described pre-
viously (Inki et al., 1994). Anti-P117 was raised against a
synthetic peptide corresponding to the cytoplasmic sequence
of human syndecan-l and subsequently purified using a
cyanogen bromide (CNBr)-activated affinity column coupled
with the peptide (Inki et al., 1994). Anti-PI 17 was shown to
react specifically with syndecan-l in Western blot and
immunohistochemical assays (Inki et al., 1994). As an inter-
nal standard, sections from histologically normal tissue from
buccal mucosa and tongue were included in each staining of
SCCs (protocols approved by the Joint Committee on Ethics
of the Turku University and the University Central Hospital
of Turku). Tissue samples were cut into 5 Im sections with a
cryomicrotome and the sections were stored at - 70°C until
use.
The sections were stained using anti-PI 17 and the
avidin-biotin immunoperoxidase (ABC) technique. After
fixing with acetone for 5 min at 4°C, the slides were
incubated with 2% normal goat serum in 0.01 M Tris-
buffered saline, pH 8.0 (TBS), for 30 min at room temper-
ature (RT), followed by anti-P117 (5 gml-1) in 1% (w/v)
BSA-TBS (Sigma, St Louis, MO, USA) overnight at 4°C.
Normal rabbit IgG (Sigma), incubated in the same way, was
used as a negative control. After washing, the slides were
incubated with Vectastain biotinylated anti-rabbit IgG for
30mmn at RT (Vector Laboratories, Burlingame, CA, USA),
followed by avidin DH-biotinylated horseradish peroxidase
H mixture for 30 min at RT (Vector Laboratories). For
colour reaction, the slides were incubated with 0.02% hydro-
gen peroxide, 0.68 mg ml-' imidazole and 0.1% (w/v)
diaminobenzdine tetrahydrochloride in 0.1 M Tris buffer,
pH 7.2, for 5min, counterstained with haematoxylin and
mounted. Staining intensity for syndecan-l was classified as:
-, negative; +, weak staining of tumour cells; +,
Table I Clinical, histological and immunohistological data
Histo- Syndecan
logical stainig Follow-up
Case Sexlage Site TNM grade intensity Treatmene statun
I F/77 Buccal T2NOMO I - S 8 months, dead
mucosa
2 M/70 Tongue T3NOMO II - S, RT 50Gy 6 months, dead
3 M/50 Hypopharynx T4NlMO II - RT 72Gy 8 months, dead
4 M/72 Nasopharynx T4N2MO II - RT 70Gy 9 months, dead
5 F/71 Nasopharynx T3N2MO III - S, RT 70Gy 12 months, dead
6 Mi68 Tonsil T3N2MO III - RT 70Gy 17 months, dead
7 M/65 Nasopharynx T1N3MO III - RT 70Gy 21 months, dead
8 F176 Gum T4NOMO I + RT 63 Gy 7 months, dead
9 F 49 Hypopharynx T4NOMO I + S, RT 65 Gy 9 months, dead
10 M/54 Floor of T2NOMO I + S, RT 65 Gy 20 months, dead
mouth
11 M/55 Larynx T4N2MO II + RT 60Gy 9 months, dead
12 M/56 Gum T3NIMO II + S, RT 65 Gy 29 months, NED
13 M/58 Tonsil T4NIMO II + S, RT 65 Gy 16 months, dead
14 M/79 Larynx T4NOMO II + RT 68Gy 8 months, dead
15 M48 Larynx T4NOMO II + S, RT 62 Gy 41 months, NED
16 F,/77 Tongue T3NOMO III + S, RT 65 Gy 10 months, dead
17 M/73 Maxillary T4NOMO III + S, RT 62 Gy 25 months, NED
sinus
18 M/52 Maxillary T4NOMO I + RT 64 Gy 14 months, dead
sinus
19 M/42 Buccal TINOMO I + S, RT 59 Gy 25 months, dead
mucosa
20 M 78 Buccal T2NOMO I + S 22 months, NED
mucosa
21 M '74 Buccal T2NOMO I + S, RT 66 Gy 24 months, NED
mucosa
22 M 44 Epiglottis T2N2MO II + S, RT 65 Gy 34 months, NED
23 M 64 Larynx T2N2MO II + S, RT 70Gy 13 months, NED
24 F 71 Tongue T2NOMO I + + S, RT 64 Gy 20 months, NED
25 M 50 Tongue T2NOMO I + + S, RT 65 Gy 19 months, NED
26 M 72 Tongue T2NlMO I + + S, RT 65 Gy 31 months, NED
27 F 93 Gum TINOMO I + + S 16 months, NED
28 M 41 Larynx TINOMO I + + RT 66 Gy 18 months, dead
29 M 38 Tongue T3NlMO II + + S, RT 64 Gy 28 months, NED
'I, well differentiated; II, moderately differentiated; III, poorly differentiated.bS, surgery; RT, radiotherapy.
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intermediate intensity of staining; or + +, strong staining,
similar to that of normal oral mucosa. Classification was
done by one author without knowledge of survival inform-
ation or other clinical data.
Statistical analysis
Survival analysis was done using a BMDP computer pro-
gram (BMDP Statistical Software, Department of Biomath-
ematics, University of California Press, Los Angeles, CA,
USA). Survival was estimated with the product-limit method,
and comparison of survival between groups was done using
the log-rank test (BMDP 1L). All P-values are two-tailed.
Frequency tables were analysed with the chi-square test or
Fisher's exact test.
Results
Expression ofsyndecan-l in SCCs ofthe head andneck
Syndecan-l was localised in frozen sections of SCCs of the
head and neck using anti-PI 17 antibody and immunohis-
tochemical methods. Anti-PI 17 has previously been shown to
react specifically with the cytoplasmic domain of human
syndecan-l core protein (Inki et al., 1994). Staining intensity
was compared with staining of normal epithelia from corres-
ponding locations, which showed strong staining of keratino-
cyte cell surfaces (Figure la). Seven (24%) SCCs showed
negative (Figure lb) and ten (34%) weakly positive staining
for syndecan-l (Table I). Intermediate staining for syndecan-
1 was observed in six (21%) (Figure lc) and strong staining
in another six (21%) SCCs (Table I, Figure ld). Intermediate
and strong positive staining for syndecan-l was localised on
cell surfaces, especially in cell-cell contact sites (Figure lc
and d).
Intermediate or strong staining for syndecan-I was
associated with small primary tumour size (P = 0.0005, Table
II). However, no association between syndecan-l expression
a
and the presence of cervical nodal metastases was found
(Table IL). Tumours that expressed syndecan-l (+ or + +)
were more often well differentiated than those that did not
express it (P =0.006, Table II). Syndecan-l expression did
not correlate significantly with age at diagnosis, WHO per-
formance status or gender (Table II).
Relationship ofsyndecan-J expression with clinical outcome
In a univariate analysis, syndecan-l staining intensity cor-
related well with overall survival and patients with a syn-
TabMe H Correlation of syndecan-l expression with six clinico-
pathological factors in SCCs of the head and neck
Svndecan-I expression
- or + or + +
Factor n (%) n (%) P-value
Tumour size
TI-2 3 (18) 10 (83)
T3 -4 14 (82) 2 (17) 0.0005
Histological grade
Well differentiated 4 (24) 9 (75)
Moderately or poorly 13 (76) 3 (25) 0.006
differentiated
WHO performance statusa
ZO- 1 12(71) 9(100)
Z2-3 5 (29) 0 (0) 0.13
Age
<65 years (median) 8 (47) 7 (58)
>65 years 9 (53) 5 (42) 0.55
Sex
Male 12 (71) 10 (83)
Female 5 (29) 2 (17) 0.66
Nodal status
NO 9 (53) 8 (67)
NI-3 8 (47) 4 (33) 0.70
'Available from 26 patients.
Figwe 1 Immunohistochemical loclisation ofsyndecan-l in normal oral mucosa a. and SCCs of the head and neck b-d. Positive
immunoreactivity is observed over the entire surface of stratified epithelial cells of normal oral mucosa, except in the most
superifical cell layers a- b, Poorly differentiated SCC of the nasopharynx lacking staining for syndecan-l (-). c-d, Well-
differentiated SCCs of the tongue showing moderate staining intensity (+) c and strong staining intensity (+ +) d for syndecan-l.
Bar, a-d, 200pm.m P. INKI et at.
decan-1-positive tumour had a more favoura
The difference in survival wassignicant both
staining groups were compared with each oth
and when tumours with strong syndecan-I ex
or +) grouped together were compared wit
negative (- or ±) tumours (Figure 2a, P =
year survival rates for syndecan-I + +, +
tumours were 80%, 80%, 30% and 0% respe
year survival rate for tumours expressng synx
++, n=17) was 81%, whereas that of
tumours with no or weak expression (- or 4
only 18%. Similarly, patients with a tumour w
expression had a higher recurrece-free surviF
with a tumour with no or lttle syndecan-I exp
survival 63% vs 18%, P=0.003, Figure 2b).
Dis d ss
We have previously shown alterations in the
syndecan-I during malignant transformation.
overall reduction of expresson found intissue
SCCs and adenocarcinomas (Inki et al., 1991,
togther with biochemical changes such as
Months
0 10 20 30
Months
Fugwe 2 Survival a, and cwurrence-free surviv
patients with SCC of the head and neck by synde
sion.
Lbleprogs. sog yan composition and increased shedding of the
when all four extracu domain ofsyndecan-l observed in cultured cells
er (P = 0.005) (Ink et al., 1992b). Furthermore, transfection ofmalignant,
pression (+ + fusiform carcioma cells with syndecan-l restores their
h syndecan-l- epithelial morphology and reduces their tumorigenicty in
0.001). The 2 nude mice (Lepp et al., 1992). These results suggest that
±, and - syndecan-l is involved in the regulation of cell morphology,
ctively. The 2 adhesion and differentiation, and that loss of syndecan-l
decan-I (+ or from transformed cells couldbe associated with uncontrolled
patients with proliferation, reducd adhesion and disurbed differentiation
, n = 12) was of tumour cells The present study is the first one to describe
ith syndecan-l the prognosticsignicance ofsyndecan-l expressonin malig-
val than those nant tumours. Syndecan-l expression was shown to correlate
ression (2 year with the clinical outcome of SCC of the head and neck, with
syndecan-l-positive tumours being associated with a more
favourable prognosis. Syndecan-I expression showed a highly
signiant association with both overall survival and
recurrence-free survival. A staistically significnt correlation
between syndecan-I expression and survival was observed
when all four saining groups were compared with each other
expression of (P =0.005), and the lowest P-value was obtained when
These include negative or weakly positive syndecan-l expression (- or ±)
sections from was com with positive expression (+ or + +)
1992a, 1994), (P=0.001).
altered glyco- Syndecan-l has previously been shown to be induced dur-
ing normal differentiation of keratinocytes (Sanderson et al.,
1992; mnuci et al., 1994). Furthermore, syndecan-I is sup-
pressed in malignant, poorly differentiated SCCs(Inci et al.,
1991, 1992a, 1994), wheas positive expression is found in
well-differentiated tumours (Inki et al., 1992a, 1993), suggest-
a ing that syndecan-l isinvolvedin keratinocyte differentiation
in both normal and malignant cells. In line with these
findings, we found a staisically signnt correlation
+ or++ between syndecan-l expression and histological differen
tiation in SCC of the head and neck. This result provides
further support for the yet unidentified role ofsyndecan-l in
keratinocyte differentiation, which is lost from aplasc
cells. However, the role ofsyndecan-l may not belimited to
cell differentiation, because the histological grade alone does
not have prognostic value in a univariate analysis in the
present series (P =0.45). The poor prognostic value of the
histological grade may be related to the limited size of the
118% seres or to the subjective nature of histological grading of
SCC (Sorensen et al., 1989). However, the prognostic value
of the histological grade in SCC of the head and neck is
currently not estabished. Although many studies have dem-
40 50 onstrated its prognostic s a (Wirnik et al., 1991), its
value has also been disputed by others (Dreyfuss & Clark,
1991; Bungaard et al., 1992; Trueson et al., 1992).
Our study showed a highly sificat association between
syndecan-I ecpression and the prinary tumour size, which
has prognstic value in a univariate survival analysis in the
present series (P=0.007) and manyothers (Bundgaard etal.,
b 1992; Cerezo et al., 1992). In addition, syndecan-l expression
was associated with the patients' WHO performance status.
Although a multivariate analysis was not carried out because
of the lmited size of the seres, in addition to syndecan-l
expresson only T-stage (P = 0.007) and WHO performance
% status (P = 0.003) showed statistclly sin t association
with survival (data not shown). This suggests thatsyndecan-l
expresson may be one of the most important prognostic
factors in SCC of the head and neck.
Treatment ofSCC ofthe head and neck is characterised by
a high recurrence rate and the frequent development of
second primary tumours (Carter, 1991; Dreyfuss & Clark,
J.1 18% 1991). TNM stag is stillthe strongestprognostic indicator in
SCC of the had and necc, whas biologial factors that
are currently used or are under investigation for the evalua-
I , tion of other carcinomas have had little significncein the
40 50 management of SCC of the head and neck (Carter, 1991).
Markers that reflect biologial properties of individual
tumours and have prognosti value would thus be valuable in
alb, of 29 the management of SCC of the head and neck, sincethey
can-I expres- could allow the individualisation of therapy. Our study
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expression and survival in this disease. Further studies on the
prognostic significance of syndecan-I expression in head and
neck cancer, as well as SCC of other body sites, are war-
ranted.
This work was supported by the Academy of Finland, the Finnish
Cancer Society, the Cancer Society of South-Western Finland, the
Turku University Foundation, the Orion Corporation Farmos
Research and Scienc Foundation and the Ida Montin Foundation.
BERNFIELD, M., KOKENYESI R. KATO, M.. HINKES, M.T., SPRING.
J.. GALLO, R.L. & LOSE. EJ. (1992). Biology of the syndecans.
Annu. Rev. Cell Biol., 8, 365-393.
BUNDGAARD, T., SORENSEN, F.B., GAIHEDE, M., SOGAARD, H. &
OVERGAARD, J. (1992). Stereologic, histopathologic, flow cyto-
metric, and clinical parameters in the prognostic evaluation of 74
patients with intraoral squamous cell carcinomas. Cancer, 70,
1-13.
CARTER, R.L. (1991). Pathology of squamous carcinomas of the
head and neck. Curr. Opin. Oncol., 3, 507-511.
CEREZO, L., MILLAND, I., TORRE, A., ARAGON, G. & OTERO. J.
(1992). Prognostic factors for survival and tumour control in
cervical lymph node metastases from head and neck cancer.
Cancer, 69, 1224-1234.
DREYFUSS, A. & CLARK, J.R (1991). Analysis of prognostic factors
in squamous cell carcinomas of the head and neck. Hematol.
Oncol. Clin. N. Am., 5, 701-712.
ELENIUS, K., SALMMRTA. M.. INKI. P.. MALI. M. & JALKANEN. M.
(1990). Binding of human syndecan to extracellular matrix pro-
teins. J. Biol. Chem., 265, 17837-17843.
ELENIUS, K., MAATITA. A.. SALMIVIRTA, M. & JALKANEN. M.
(1992). Growth factors induce 3T3 cells to express bFGF-binding
syndecan. J. Biol. Chem., 267, 6435-6441.
FOLKMAN. JI & SHING, Y. (1992). Control of angiogenesis by
heparin and other sulfated polysaccharides. In Heparin and
Related Polvsaccharides, Lane, D.A., Bjrlk, I. & Lindahl, U.
(eds) pp. 355-364. Plenum Press: New York.
GALLAGHER, J.T. (1989). The extended family of proteoglycans:
social residents of the pericellular zone. Curr. Opin. Cell Biol., 1,
1201-1218.
HAYASHI, K. HAYASHI, M, JALKANEN, M.. FIRESTONE, J.H..
TRELSTAD, R.L. & BERNFIELD, M. (1987). Immunocytochemistry
of cell surface heparan sulfate proteoglycan in mouse tissues. A
light and electron microscopic study. J. Histochem. Cytochem.,
35, 1079-1088.
INKI. P., SrENBACK. F.. TALVE. L. & JALKANEN, M. (1991).
Immunohistochemical localization of syndecan in mouse skin
tumours induced by UV irradiation. Loss of expression
associated with malignant transformation. Am. J. Pathol., 139,
1333-1340.
INKI, P., KUJARI, H. & JALKANEN, M. (1992a). Syndecan in car-
cinomas produced from transformed epithelial cells in nude mice.
Lab. Invest., 66, 314-323.
INKI P., GOMEZ, M., QUINTANILLA, M.. CANO. A. & JALKANEN.
M. (1992h). Expression of syndecan in transformed mouse
keratinocytes. Lab. Invest., 67, 225-233.
INKI, P., LARJAVA, H., HAAPASALMI, K, MIEITrINEN, H.M., GREN-
MAN, R. & JALKANEN, M. (1994). Expression of syndecan-1 is
induced by differentiation and suppressed by malgnant transfor-
mation of human keratinocytes. Eur. J. Cell. Biol., 63, 43-51.
JALKANEN, M., JALKANEN, S. & BERNFIELD, M. (1991). Binding of
extracellular effector mokcules to cell surface proteoglycans. In
Receptors for Extracelhdlar Matrix, McDonald, J.A. & Mecham,
R.P. (eds) pp. 1-37. Academic Press: San Diego.
JALKANEN, M., ELENIUS, K. & RAPRAEGER, A. (1993). Syndecan:
regulator of cell morphology and growth factor action at the
cell-matrix interface. Trends Glvcosci. Glvcotechnol., 5, 107-120.
KIEFER, M.C.. STEPHANS. J.C-, CRAWFORD, K., OKINO. K. & BARR.
PJ. (1990). Ligand-affinity cloning and structure of a cell surface
haparan sulfate proteoglycan that binds basic fibroblast growth
factor. Proc. Nati Acad. Sci. USA, 87, 6985-6989.
LEPPA, S., MALI, M.. MIETTINEN. H. & JALKANEN, M. (1992).
Syndecan expression regulates cell morphology and growth of
mouse mammary epithelial tumour cells. Proc. Natil. Acad. Sci.
USA, 89, 932-936.
LIOTFTA. LA_. RAO. C.N. & WEWER. UM. (1986). Biochemical
interactions of tumour cells with the basement membrane. Annu.
Rev. Biochem., 55, 1037-1051.
MILLER, A.B.. HOOGSTRATEN, B.. STAQUET. M. & WINKLER. A.
(1981). Reporting results of cancer treatment Cancer, 47,
207-214.
NAVARRO, P., GOMEZ, M., PIZARRO, A., GAMALLO, C., QUIN-
TANILLA, M. & CANO. A. (1991). A role for the E-cadherin
cell-cell adhesion molecule during tumour progression of mouse
epidermal carcinogenesis. J. Cell Biol., 115, 517-533.
RUOSLAHTI, E. (1991). Integrins. J. Clin. Invest., 87, 1-5.
SALMIVIRTA, M., ELENIUS, K, VAINIO, S., HOFER, U., CHIQUET-
ERICHSMAN, R-, THESLEFF, I. & JALKANEN, M. (1991).
Syndecan from embryonic tooth mesenchyme binds tenascin. J.
Biol. Chem., 266, 7733-7739.
SALMIVIRTA, M., HEINO. J. & JALKANEN, M. (1992). Basic fibro-
blast growth factor-syndecan complex at cell surface or
immobilized to matrix promotes cell growth. J. Biol. Chem., 267,
17606- 17610.
SANDERSON, R., HINKES, M. & BERNFIELD, M. (1992). Syndecan-1,
a cell-surface proteoglycan, changes in size and abundance when
keratinocytes stratify. J. Invest. Dermatol., 99, 390-3%.
SAUNDERS, S., JALKANEN, M., O'FARREL, S. & BERNFIELD, M.
(1989). Moleclar cloning of syndecan, an integral membrane
proteoglycan. J. Cell Biol., 1iN, 1547-1565.
SCHIPPER, J.H.. FRIXEN. U.H., BEHRENS, J., UNGER. A., JAHNKE,
K. & BIRCHMEIER. W. (1991). E-Cadherin expression in
squamous cell carcinomas of the head and neck: inverse correla-
tion with tumour dedifferentiation and lymph node metastasis.
Cancer Res., 51, 6328-6337.
SHAMUGARATNAM, K. & SOBIN, L.H. (1978). Histological Typing of
Upper Respiratory Tract Twnours. pp. 14, 33. WHO: Geneva.
SORENSEN, F.B., BANNEDBAEK. O., PILGAARD, JI & SPAUN, E.
(1989). Stereological estimation of nuclear volume and other
quantitative histopathological parameters in the prognostic
evaluation of supralottic laryngeal squamous cell carcinoma.
APMIS, 97, 987-995.
SUN, X., MOSHER, D.F. & RAPRAEGER, A. (1989). Heparan sulfate-
mediated binding ofepithelial cell surface proteoglycan to throm-
bospondin. J. Biol. Chem., 264, 2885-2889.
SUTHERLAND, A.E., SANDERSON, RD., MAYES, M_ SIEBERT, M.,
CARLACO, PG. & BERNFIELD, M. (1991). Expression of
syndecan, a putative low affinity fibroblast growth factor recep-
tor, in the early mouse embryo. Development, 113, 339-351.
TAKEICHI, M. (1991). Cadherin cell adhesion receptors as a mor-
phogenetic regulator. Science, 251, 1451-1455.
THESLEFF, I., JALKANEN, M., VAINIO, S. & BERNFIELD. M. (1988).
Cell surface proteoglycan expression correlates with epithe-
lial-mesenchymal interaction during tooth morphogenesis. Dev.
Biol., 129, 565-572.
TRUELSON. J.M., FISHER, SG., BEALS, T.E.. McCLATCHEY. K.D.,
WOLF, G.T. & THE DEPARTMENT OF VETERANS AFFAIRS
COOPERATIVE LARYNGEAL CANCER STUDY GROUP (1992).
DNA content and histological growth pattern correlate with
prognosis in patients with advanced squamous cell carcinoma of
the larynx. Cancer, 70, 56-62.
VAINIO, S. & THESLEFF, I. (1992). Sequential induction of syndecan,
tenascin and cell proliferation associated with mesenchymal cell
condensation during early tooth development. Differentiation, 50,
97- 105.
VAINIO, S. LEHTONEN. E., JALKANEN. M. BERNFIELD. M. &
SAXEN. L. (1989). Epithelial-mesenchymal interactions regulate
the stage-specific expression of a cell surface proteoglycan,
syndecan, in the developing kidney. Dev. Biol., 134, 382-391.
VIRTANEN. I., KORHONEN. M., KARINIEMI. A.-L.. GOULD, V.E.,
LAnITNEN, L. & YLXNNE, J. (1990). Integrins in human cells and
tumours. Cell Different. Dev., 32, 215-228.
WEINSTEIN. R-S., MERK. F.B. & ALROY. J. (1976). The structure and
function of intercellular junctions in cancer. Adv. Cancer Res., 23,
25-33.
WIERNIK. G.. MILLARD. P.R. & HAYBrITLE. J.L. (1991). The
predictive value of histological classification into degress of
differentiation of squamous cell carcinoma of the larynx and
hypopharynx compared with the survival of patients. Histo-
pathology, 19, 411-417.